SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: GlobeNewswire
Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the second quarter ended September 30, 2024, and provided a company update. “This quarter we were pleased to report completed enrollment of SAB-142 Phase 1 study with no observed serum sickness,” notes SAB chairman and CEO Samuel J. Reich. “This year we have advanced our SAB-142 Type 1 diabetes program from preclinical through Phase I to Phase II ready, which illustrates SAB management’s ability to execute our business strategy according to plan. Enthusiasm for SAB
Show less
Read more
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.MarketBeat
- SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation ConferenceGlobeNewswire
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $11.00 price target on the stock.MarketBeat
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into SAB Biotherapeutics, Inc.Accesswire
SABS
Earnings
- 11/6/24 - Miss
SABS
Sec Filings
- 11/6/24 - Form 10-Q
- 11/5/24 - Form 4
- 9/9/24 - Form 8-K
- SABS's page on the SEC website